Biological Psychiatry is a premier journal dedicated to advancing the understanding of the biological underpinnings of psychiatric disorders. Published by Elsevier Science Inc, this esteemed journal is recognized globally for its rigorous peer-reviewed research and contributes significantly to the field of biological psychiatry. With an impressive impact factor that places it in Q1 of its category and ranks 3rd out of 51 in Neuroscience Biological Psychiatry, it reflects the journal's strength in disseminating high-quality findings that push the boundaries of knowledge. Since its inception in 1969, the journal has undergone continuous evolution, aiming to integrate biological and clinical perspectives to optimize the understanding of mental health conditions. Although it does not offer open access, Biological Psychiatry serves as a critical resource for researchers, practitioners, and students, offering insights that influence both theoretical frameworks and practical applications in the realm of psychiatric science.

General Psychiatry is a leading open-access journal published by BMJ PUBLISHING GROUP, dedicated to advancing the field of psychiatry and mental health. With an impressive impact factor and ranked in the Q1 category across various related disciplines—including Psychiatry and Mental Health, as well as Clinical Neurology—this journal offers a vital platform for researchers and practitioners in the field to disseminate high-quality studies and insights. The journal has been open access since 2018, ensuring that the latest research is freely available to a global audience, thus fostering greater collaboration and innovation. With a focus on significant developments and emerging trends, General Psychiatry serves as an essential resource for professionals keen on improving mental health practices and understanding neurological aspects of mental disorders. The journal is based in the United Kingdom, reflecting a commitment to global health discussions and initiatives in psychiatry.

JOURNAL OF PSYCHIATRY & NEUROSCIENCE, published by the CMA-Canadian Medical Association, serves as a pivotal platform for disseminating cutting-edge research in the fields of psychiatry and neuroscience. This esteemed journal, indexed with the ISSN 1180-4882 and E-ISSN 1488-2434, focuses on advancing our understanding of mental health through meticulous peer-reviewed articles, reviews, and clinical studies. With an impressive impact within the research community, it has achieved notable rankings, including Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health, as well as Q2 in Biological Psychiatry as of 2023. The journal fosters critical dialogue among scholars and practitioners by offering insights into the complexities of brain function and mental disorders, making it a fundamental resource for healthcare professionals, researchers, and students alike. Although it operates under a subscription model, its rich content continues to inform and influence the advancement of mental health science, affirming its role in bridging the gap between research and clinical practice.

EUROPEAN NEUROPSYCHOPHARMACOLOGY, published by Elsevier, is a prestigious academic journal that serves as a cornerstone in the field of neuropsychopharmacology, embracing multidisciplinary research at the intersection of neuroscience, psychiatry, and pharmacology. Since its establishment in 1990, this journal has consistently delivered cutting-edge research and reviews that drive forward our understanding of central nervous system disorders and their treatment. With an impressive impact factor and ranked in the Q1 category for several disciplines, including Biological Psychiatry and Neurology, it attracts submissions from leading researchers globally. The journal’s Scopus rankings reflect its significant influence, ranking in the top echelons across various categories such as Medicine and Neuroscience. While the journal maintains subscription access, readers are encouraged to explore the breadth of important findings that contribute to advancements in treatment options and improve patient care. EUROPEAN NEUROPSYCHOPHARMACOLOGY not only supports the dissemination of pivotal research but also fosters collaboration and dialogue within the scientific community, making it an essential resource for researchers, clinicians, and students dedicated to the complexities of brain health.

Middle East Current Psychiatry (MECPsych), published by SpringerNature, is a prominent open-access journal dedicated to advancing the field of psychiatry and mental health in the Middle East and beyond. Since its establishment in 2011, MECPsych has aimed to disseminate high-quality research, reviews, and reports that capture recent developments in psychiatric science, clinical practice, and public health considerations in mental well-being. With an impact factor reflective of its growing influence and classified in the Q3 quartile for Psychiatry and Mental Health, the journal offers invaluable insights backed by rigorous peer review processes. Operating under an open access model since 2019, MECPsych ensures that its articles are freely accessible to a global readership, enhancing the visibility and application of research findings. As part of its ongoing commitment to enriching understanding in the field, MECPsych also encourages submissions that explore the unique cultural, societal, and economic factors influencing mental health across the region. This approach not only supports researchers, professionals, and students in their pursuit of knowledge but also fosters a collaborative dialogue among mental health stakeholders in the Middle East and around the world.

Asia-Pacific Psychiatry is a leading academic journal published by WILEY, focused on the diverse and rapidly evolving fields of psychiatry and mental health within the Asia-Pacific region. With an ISSN of 1758-5864 and an E-ISSN of 1758-5872, this journal has been recognized for its significant impact, holding a Q1 ranking in Medicine (miscellaneous) and a Q2 ranking in Psychiatry and Mental Health as of 2023. Its commendable Scopus ranking places it at Rank #83 out of 567 in its category, highlighting its influence and relevance in contemporary research. The journal aims to facilitate the dissemination of high-quality research, reviews, and clinical insights that address mental health challenges, promote global understanding, and encourage collaboration among professionals and academics. Although it is not an open-access journal, the high impact factor underscores its value in the scholarly community, making it an essential resource for researchers, clinicians, and students dedicated to enhancing mental health practices and policies in the region and beyond.

Behavioural Pharmacology is a distinguished academic journal published by Lippincott Williams & Wilkins, focusing on the intricate relationship between pharmacology, psychiatry, and behavioral science. With an ISSN of 0955-8810 and an E-ISSN of 1473-5849, this journal serves as a vital platform for researchers and professionals dedicated to exploring the pharmacological mechanisms underlying behavior and mental health. Operating with a robust track record since its inception in 1992, it has established itself in the academic community, as reflected by its Q3 rankings in both the pharmacology and psychiatry categories for 2023. Additionally, the journal holds a credible position in Scopus rankings, with a percentile ranking indicative of significant contributions to the fields of pharmacology and psychiatry. Aimed at advancing knowledge and disseminating research in the behavioral pharmacology domain, this journal is an essential resource for students, researchers, and clinical professionals seeking to stay at the forefront of this rapidly evolving field. While it is not an open access journal, the rich content and research findings published here continue to foster collaboration and innovation within the community, making it a crucial reference point for current and future studies.

Psychiatria Polska is a distinguished journal published by WYDAWNICZY POLSKIEGO TOWARZYSTWA, focused on advancing the field of psychiatry and mental health. Established in 1967, this journal has become a vital resource for researchers, clinicians, and students, contributing to the understanding of psychiatric disorders and their treatments. With an ISSN of 0033-2674, it features a diverse range of studies, case reports, and reviews, making it an essential platform for sharing innovative findings within the psychiatric community. Although currently categorized in the Q3 quartile for both Medicine (miscellaneous) and Psychiatry and Mental Health in 2023, its increasing impact is evidenced by its Scopus ranking of #345 out of 567 in its category, placing it in the 39th percentile. Located in Cracow, Poland, Psychiatria Polska continues to foster international collaboration and knowledge exchange, despite being non-open access, ensuring that its high-quality content reaches a wide audience. This journal is dedicated to enhancing the dialogue on mental health, making it an indispensable resource for those committed to improving psychiatric practice and research.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, a premier academic journal published by TAYLOR & FRANCIS LTD, stands at the forefront of interdisciplinary research in the fields of Biological Psychiatry, Psychiatry, and Mental Health. Based in the United Kingdom, this esteemed journal (ISSN: 1562-2975; E-ISSN: 1814-1412) has become increasingly influential since its inception in 2000, with a remarkable impact factor that reflects its high-quality research contributions. The journal is consistently ranked in the Q1 and Q2 categories across various relevant indices, demonstrating its reputation for excellence within the academic community. With Scopus rankings placing it in the top 20th percentile for Psychiatry and Mental Health, the WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY serves as a vital resource for researchers, professionals, and students seeking to further their understanding of the intricate relationship between biological processes and psychiatric phenomena. Despite being a traditional access journal, it possesses a robust scope that encompasses groundbreaking studies, reviews, and advancements in the understanding of mental health disorders, underlining its importance as a key reference in the advancement of psychiatric science and therapeutic practices.

JAMA Psychiatry, published by the American Medical Association, stands as a leading peer-reviewed journal in the fields of psychiatry and mental health, featuring an impressive impact factor that reflects its significance in advancing research and clinical practice. With an ISSN of 2168-622X and an E-ISSN of 2168-6238, this journal operates on a comprehensive access model that allows for the dissemination of vital research findings to a global audience. Since its inception in 2013, JAMA Psychiatry has consistently ranked in the top quartile (Q1) in both the Medicine (miscellaneous) and Psychiatry and Mental Health categories, with a remarkable Scopus rank of #4 out of 567, placing it in the 99th percentile. Addressed from its headquarters in Chicago, Illinois, the journal's objectives encompass the publication of original clinical research, innovative treatment strategies, and insightful reviews that enrich the understanding of psychiatric disorders. By bridging the gap between research and real-world application, JAMA Psychiatry remains an essential resource for researchers, clinicians, and students dedicated to improving mental health outcomes.